Are you looking for the best medical billing option for your pharmacy? Look no further! TransactRxĀ®, a RedSail company, helps pharmacies capture all the reimbursements owed from immunizations and clinical services. Using RedSail Medical Billing, pharmacies get their claims submitted, payments posted, and outstanding issues resolved.
Sign up by April 30 for $0 enrollment ($650 savings).
The DeliveryTrack mobile app is now available on the AppleĀ® App Store and Google Playā¢! Want to deliver more for your customers? See how you can simplify your pharmacy delivery process, maximize efļ¬ciency, and grow your business with DeliveryTrack.
Yardi Interface with DocuTrack
You asked. We listened! Integra is proud to announce DocuTrackās interface with Yardi eMAR ā further eliminating the need for paperwork in medication administration. With this partnership, you can:
Reduce phone calls or faxes to your pharmacy by electronically sending refill requests, discontinued medication notifications, and census-type communications
Improve collaboration between nursing home and pharmacy staff
Maintain compliance with up-to-date records
Enhance overall resident care
Interested? To initiate the set-up process, please contact Sales at 866.257.4279.
HHS Initial Guidance for Medicare Drug Price Negotiation
Due to the Inflation Reduction Act, Medicare will be able to negotiate directly with drug companies for lower prices on selected drugs. The guidance details requirements of the new Medicare Drug Price Negotiation Program for 2026. HHS Secretary Xavier Becerra said, āThrough theā¦ Program, we will make sure seniors get a fair price on Medicareās costliest prescription drugs, promote competition in the market, and ensure Medicare is strong for beneficiaries today and into the future.ā
FDA Final Guidance on Definitions of Suspect and Illegitimate Product
As part of implementation of the Drug Supply Chain Security Act, the FDA has issued the final guidance for āDefinitions of Suspect Product and Illegitimate Product for Verification Obligations.ā It clarifies the FDAās interpretation of the terms counterfeit, diverted, stolen, fraudulent transaction, and unit for distribution. The guidance is intended to help the industry identify suspect and illegitimate product in the U.S. pharmaceutical distribution supply chain.
The House Committee on Oversight and Accountability has launched an investigation into the questionable business practices of pharmacy benefit managers (PBMs). Committee Chairman James Comer (R-KY) said, āGreater transparency in the PBM industry is vital to determine the impact that their tactics are having on patients, the pharmaceutical market, and health care programs administered by the federal government.ā
This investigation, along with the Federal Trade Commission inquiry, and recent legislative developments are putting pressure on PBMs.
Join us May 10-12 in Grapevine, TX, for the annual GeriMed Conference. The spotlight will be on all things affecting the LTC pharmacy industry. Visit the Integra team at Booth #507 to see AxysĀ® ā our cloud-based pharmacy management software ā in action. Itās time to explore what something new can do for your pharmacy.
Ryan Oftebro, PharmD, FACA, CEO of independent Kelley-Ross Pharmacy Group, joins us for an open conversation about pharmacy benefit managers (PBMs) fresh off his testimony on Capitol Hill. Oftebro spoke to the Senate Committee on Commerce, Science, and Transportation during a hearing addressing how the āPharmacy Benefit Manager Transparency Actā will bring transparency into PBM business practices and prohibit unfair or deceptive PBM conduct.
Are you familiar with biosimilars? They are not identical to reference products, but they offer potential cost savings and expand patients' access to advanced treatments. With major drug patents expiring soon, there are vast opportunities for biosimilar introductions. As the adoption of biosimilars continues to rise, it's crucial to understand the basics, including the regulatory landscape and interchangeability. Explore the nuanced approval processes, advantages, and obstacles of biosimilars today.
